Biotech companies — private and public — pulled in roughly $4.9 billion in financing in the run‑up to the JP Morgan Healthcare Conference, with private biotechs raising at least $2.29 billion during the first week of January, Endpoints and BioCentury reported. The flurry included mega‑rounds, seed and crossover financings, and follow‑on public offerings, reflecting elevated investor interest tied to the conference calendar. Market participants noted dealflow is accelerating earlier in the year, with capital chasing both platform bets and late‑stage assets.